Astera Labs, Inc. director Jack R. Lazar entered a securities transaction on March 16, 2026, selling 2,500 shares of the company’s common stock at $130.00 per share, producing gross proceeds of $325,000. The disposition was processed automatically under a pre-established Rule 10b5-1 trading plan that Lazar adopted on December 2, 2025.
Following the sale, Lazar retains direct ownership of 84,851 shares of Astera Labs. At the time of the transaction the market price for Astera Labs stock was $127.56. That level sits substantially below the security’s 52-week peak of $262.90, though the share price remains 77% higher than it was one year earlier.
Independent analysis cited in connection with the transaction indicates that the stock currently appears overvalued relative to its Fair Value, according to InvestingPro. A related company Pro Research Report is available for ALAB alongside coverage for more than 1,400 other U.S. equities, providing a more detailed valuation and fundamentals review for investors that seek it.
Separately from the insider activity, Astera Labs released fourth-quarter 2025 financial results that showed the company exceeded consensus earnings expectations. Reported earnings per share came in at $0.58, beating the anticipated $0.51 per share by 13.73%. Revenue for the quarter reached $270.6 million, a year-over-year increase of 92%.
Those quarterly outcomes underscore a period of strong top-line growth and an earnings beat in the latest reported period. No mergers or acquisitions were announced for the quarter, and the company’s recent updates did not include any analyst rating changes.
The transaction by Lazar was executed under an automatic trading arrangement and therefore did not represent a discretionary, ad hoc sale on his part. Investors assessing the stock have both the insider transaction details and the most recent operating results to consider as they evaluate valuation, momentum, and corporate-level developments.
Additional product offerings and analytic tools referenced in company coverage include algorithmic strategy screening. One such tool, ProPicks AI, is described as evaluating companies monthly on more than 100 financial metrics to identify stocks it views as offering favorable risk-reward profiles; the tool is noted as having previously highlighted names that subsequently produced sizable returns. Interested investors may consult those services to see whether ALAB appears in active strategy sets or to compare opportunities in the same space.